Savara Inc (SVRA) Stock Analysis

Savara Inc (SVRA) is a publicly traded company in the HEALTHCARE sector. It trades at $5.25, carries a market capitalization of $1.06B. This page summarizes the public market data, fundamentals, and frequently asked questions for SVRA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.25
• Market Cap: $1.06B
• EPS: $-0.56
• 52-Week High: $7.00
• 52-Week Low: $1.98

Market Sentiment

Savara Inc currently has a Bullish sentiment score of 0.16.

About Savara Inc

Savara Inc. is a biopharmaceutical company headquartered in Austin, Texas, focused on developing innovative therapies for patients with rare lung diseases. With a commitment to addressing unmet medical needs in the field of respiratory health, Savara's pipeline includes promising candidates targeting various orphan indications. The company's strategic approach combines cutting-edge science with a patient-centric vision, positioning it as a key player in the lung disease therapeutic landscape.

GNG Research Analysis

GNG Research scores Savara Inc (SVRA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SVRA.

Frequently Asked Questions

Does SVRA pay dividends?

Savara Inc (SVRA) does not currently pay a regular dividend.

What is SVRA's market cap?

Savara Inc (SVRA) has a market capitalization of $1.06B with a current stock price of $5.25.